8-K: Aclarion Secures $2.5M in Direct Offering

Aclarion, Inc. announced a registered direct offering of common stock and pre-funded warrants, raising approximately $2.5 million to fund market and product development, and clinical trials.

Summary

• Aclarion, Inc. entered into a Securities Purchase Agreement on October 13, 2025, for a registered direct offering.
• The offering includes the sale of 64,000 shares of common stock at a price of $8.36 per share.
• Additionally, pre-funded warrants to purchase up to 236,000 shares of common stock were sold.
• The pre-funded warrants are immediately exercisable with a nominal exercise price of $0.00001 per share.
• Gross proceeds from the offering are expected to be approximately $2.5 million.
• Net proceeds will be used for market development, clinical evidence (The Clarity Trial), product development and quality, general and administration support, and other general corporate purposes.
• Dawson James Securities, Inc. served as the exclusive placement agent, receiving a 7.0% cash fee of the gross proceeds and reimbursement of certain expenses.
• The offering is expected to close on or about October 14, 2025.

Sentiment

Score: 7

Explanation: The capital raise provides necessary funding for strategic initiatives like clinical trials and product development, which is positive for long-term growth. While there is dilution, the company has also implemented a 60-day lock-up on further equity sales, which mitigates immediate additional dilution concerns. The use of proceeds is clearly defined for growth-oriented activities.

Positives

• Successfully raised approximately $2.5 million in gross proceeds, strengthening the company's financial position.
• Funds are earmarked for strategic growth initiatives including market development, clinical evidence (The Clarity Trial), and product development.
• The company has committed to a 60-day lock-up period on further equity issuances (with specific exceptions), limiting immediate additional dilution.
• The offering was made pursuant to an effective S-3 registration statement, indicating readiness for public offerings.

Negatives

• The offering involves the issuance of new common stock and pre-funded warrants, leading to dilution for existing shareholders.
• A 7.0% cash fee, plus expense reimbursements, will be paid to the placement agent, reducing the net proceeds available to the company.
• The pre-funded warrants have a very low exercise price ($0.00001), meaning they are almost fully paid for and will convert into shares with minimal additional cash to the company upon exercise.

Risks

• General market conditions could impact the company's ability to complete the offering on favorable terms, or at all.
• The company's ability to successfully complete the offering is subject to various risks.
• Other risks detailed in the company's Annual Report on Form 10-K for the year ended December 31, 2024, and Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, could cause actual results to differ from current expectations.

Future Outlook

The company intends to use the net proceeds from the offering to fund market development, clinical evidence (specifically The Clarity Trial), product development and quality initiatives, and general and administration support, alongside other general corporate purposes.

Management Comments

• The report was signed by Gregory A. Gould, Chief Financial Officer, on October 14, 2025.

Industry Context

The filing does not provide specific details to analyze this announcement in relation to broader industry trends or competitors. However, capital raises are common for medical technology companies like Aclarion to fund ongoing research, development, and market expansion, particularly for clinical trials such as 'The Clarity Trial'.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Will experience dilution from the issuance of new common stock and pre-funded warrants, but the capital raise provides funding for future growth initiatives.
• Company Operations: Will benefit from increased capital to fund critical market development, clinical trials, and product development, potentially accelerating growth and innovation.

Next Steps

• Closing of the offering on or about October 14, 2025, subject to customary conditions.
• Use of net proceeds to fund market development, clinical evidence (The Clarity Trial), product development and quality, and general and administration support.
• Company will apply to list all new shares and warrant shares on Nasdaq Stock Market.
• Company will maintain listing on Nasdaq and comply with reporting obligations.

Key Dates

Recommendation

The capital raise provides essential funding for Aclarion's strategic growth initiatives, including clinical trials and product development, which is a positive for the company's long-term prospects. However, the offering introduces dilution for existing shareholders. The 60-day lock-up on further equity sales offers some near-term stability against additional dilution. Given the balance of funding for growth against the immediate dilution, a 'hold' recommendation is appropriate for investors to observe the execution of the funded initiatives and their impact on future performance.

Keywords

Aclarion, ACON, Direct Offering, Common Stock, Pre-funded Warrants, Capital Raise, SEC Filing, Market Development, Clinical Trials, Product Development, Nasdaq